The U.S. Food and Drug Administration (FDA) has granted initial approval for a generic version of Dapagliflozin (ANDA 211531) on April 6, 2026. This regulatory action, sponsored by LUPIN, signifies the availability of a new generic equivalent for the branded drug.
Background
Dapagliflozin is the active pharmaceutical ingredient in several medications, including combination products such as dapagliflozin and metformin hydrochloride, xigduo xr, and dapagliflozin and saxagliptin. It is also known by the brand name Farxiga. The approval of an Abbreviated New Drug Application (ANDA) like ANDA 211531 indicates that the generic formulation has demonstrated bioequivalence to its reference listed drug, meeting the FDA's rigorous standards for quality, safety, and efficacy. This ensures that the generic version provides the same clinical benefits as the original branded product.
What this means
The initial FDA approval of a generic version of Dapagliflozin is a significant development for patients and healthcare systems. Generic approvals typically lead to increased market competition, which can result in greater accessibility and potentially lower costs for the medication. This expansion of treatment options provides therapeutically equivalent alternatives, making essential drugs more affordable and widely available to those who need them.
Source
The information regarding this initial approval was obtained from the U.S. Food and Drug Administration (FDA) website. The approval for ANDA 211531, pertaining to Dapagliflozin, was granted on April 6, 2026, and is publicly accessible on accessdata.fda.gov.